News

Enterin’s ENT-01, a compound that targets and reduces the accumulation of alpha-synuclein in nerve cells found in the gut, may slow the progression of Parkinson’s disease, according to a review study. The review, “Gastrointestinal Immunity and Alpha-Synuclein,” was published in the Journal…

A calcium channel called Cav2.3 plays a role in neuronal death, and may be a useful therapeutic target in Parkinson’s disease, suggests a new study done primarily in mice. The study, titled “Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease,” was published…

A new application for Android tablets, called SleepFit, may help to monitor the daily progression and response to treatment of motor symptoms associated with Parkinson’s disease, according to a study. The application was evaluated in the study “A New Prospective, Home-Based Monitoring of Motor Symptoms in Parkinson’s…

As part of a new partnership with Parkinson’s UK, the Parkinson’s Foundation has granted the nonprofit $250,000 toward a prospective new treatment linked to mitochondrial function that is being developed in the Parkinson’s Virtual Biotech program. The grant will help advance a project aimed at uncovering new methods…

A new biosensor system may make it easier to monitor stem cells changing into mature cells like neurons, which could allow for a better understanding of diseases like Parkinson’s and support the development of new treatments. The system was described in the paper, “Dual-Enhanced Raman Scattering-Based Characterization of…

Contrary to what is commonly thought, dopamine-producing nerve cells (neurons) that stop functioning in Parkinson’s disease may not die, but instead enter a state of senescence in which they cease to divide and cause damage to healthy neighboring cells, a study found. In fact, one researcher noted these senescence cells…

Studies on gut bacteria in Parkinson’s disease differ in their findings and important methodological details, according to a new review that highlights these differences and proposes strategies to mitigate them in the future. The study, titled “Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease:…

Earlier onset of disease, early impairment of memory and thinking, and higher daily use of antiparkinson medication, are associated with increased risk of death related to Parkinson’s disease (PD), according to a study that followed newly diagnosed patients for more than 10 years. Conversely, being male, the severity of…

A specific form of magnesium taken orally and able to readily enter the brain was seen to ease Parkinson’s-related motor problems and nerve cell loss in a mouse model of the disorder. The study, “Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits…

Parkinson’s disease may be classified by into two distinct subtypes based on where in the nervous system the disease starts, a study proposes. Its findings could have major implications for the development of new treatments. The paper, “Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis,” was published in…